Evidence map›Paper›PMID 41724964›Full record

ArticleEpigenetics & chromatin2026

High-resolution map of chromatin accessibility - insights into the focused binding of a large number of transcription factors.

Iris Zhu, David Landsman

Abstract read
In one paragraph

Article in Epigenetics & chromatin, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Iris ZhuDivision of Intramural Research, National Library of Medicine, National Institutes of Health, Bethesda, MD, USA. zhuz2@nih.gov.
David LandsmanDivision of Intramural Research, National Library of Medicine, National Institutes of Health, Bethesda, MD, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEmerging evidence has shown the common occupancy of dozens to hundreds of transcription factors (TFs) on cis-regulatory elements (CREs), yet the underlying details are largely unknown.

resultsIn this study, leveraging extensive collections of TF ChIP-seq data of more than 1000 TFs in human HepG2 and K562 cells, we located highly focused TF binding sites (FBSs) within CREs as single-nucleosome depleted regions, which accommodate the majority of the total TF binding events. Approximately 25,000 strong FBSs were identified in each cell type. For more than 90% of TFs, including some pioneer factors such as GATA1 and JUN, their binding sites out of FBSs barely show nucleosome depletion. Essential cellular function related motifs and phenotypically causal variants are strongly enriched in the FBSs, but not in their immediate flanking regions within CREs. Most TFs bind to FBSs not containing their canonical motifs.

conclusionOur study revealed the critical connection between highly focused TF binding and the nucleosome depleted status of DNA in vivo. Meanwhile, we constructed high-resolution maps of chromatin accessibility at distal CREs in the two human cells. We propose a model of TF co-binding in vivo and suggest that a short DNA residence time of most TFs underlies the requirement of a large number of TFs for sustained nucleosome depletion at CREs.

Indexed as

ChromatinTranscription FactorsBinding SitesChromatin Immunoprecipitation SequencingHep G2 CellsHumansK562 CellsNucleosomesProtein BindingChromatinNucleosomesTranscription FactorsChromatin accessibilityFocused binding of a large number of TFsNucleosome depletion

Identifiers

PMID41724964
PMCPMC13032593

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.